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Background: Clinical guidelines vary in determining optimal blood pressure targets in adults with diabetes
mellitus.
Methods: We systematically searched PubMed, EMBASE, Cochrane Library, and clinicaltrials.gov in
March 2018; conducted random effects frequentist meta-analyses of direct aggregate data; and appraised
the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation
(GRADE) methodology.
Results: From eligible 14 meta-analyses and 95 publications of randomized controlled trials (RCT), only
6 RCTs directly compared lower versus higher blood pressure targets; remaining RCTs aimed at comparative
effectiveness of hypotensive drugs. In adults with diabetes mellitus and elevated systolic blood pressure (SBP),
direct evidence (2 RCTs) suggests that intensive target SBP <120–140 mmHg decreases the risk of diabetes-related
mortality [relative risk (RR) =0.68; 95% confidence interval (CI), 0.50–0.92], fatal (RR =0.41; 95% CI, 0.20–0.84)
or nonfatal stroke (RR =0.60; 95% CI, 0.43–0.83), prevalence of left ventricular hypertrophy and
electrocardiogram (ECG) abnormalities, macroalbuminuria, and non-spine bone fractures, with no differences
in all-cause or cardiovascular mortality or falls. In adults with diabetes mellitus and elevated diastolic
blood pressure (DBP) ≥90 mmHg, direct evidence (2 RCTs) suggests that intensive DBP target ≤80 versus
80–90 mmHg decreases the risk of major cardiovascular events. Published meta-analyses of aggregate
data suggested a significant association between lower baseline and attained blood pressure and increased
cardiovascular mortality.
Conclusions: We concluded that in adults with diabetes mellitus and arterial hypertension, in order
to reduce the risk of stroke, clinicians should target blood pressure at 120–130/80 mmHg, with close
monitoring for all drug-related harms.
Keywords: Quality of evidence; cardiovascular morbidity; diabetes mellitus; arterial hypertension; blood pressure
targets
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Introduction
One of the main goals in managing type 2 diabetes in adults
is prevention of cardiovascular morbidity or mortality by
controlling blood glucose, normalizing blood pressure, and
reducing other cardiovascular risk factors (1,2). Despite
extensive review of literature, clinical practice guidelines
vary in determining the optimal blood pressure targets in
patients with diabetes (3-5).
To support clinical decisions at point of care with all
available evidence, we conducted a rapid review of the
published and unpublished data from recently completed
randomized controlled trials (RCT), meta-analyses of
RCTs, and primary observational studies that compared
different blood pressure targets in adults with diabetes.
Methods
We used a standard recommended methodology in
conducting systematic literature reviews and meta-analyses
from the Cochrane Collaboration and the Agency for
Healthcare Research and Quality (6,7). We developed
a priori protocol (available by request) for a systematic
literature review to answer the clinical question about
the comparative effectiveness of blood pressure targets
on mortality and cardiovascular morbidity in adults with
diabetes mellitus.
Eligible studies directly compared lower versus higher
blood pressure targets or examined the association between
baseline or attained blood pressure with patient outcomes
in people treated with hypotensive medications. Eligible
outcomes included all-cause and underlying cause-specific
mortality, cardiovascular morbidity, stroke, heart failure,
renal failure, and all drug harms.
We conducted a comprehensive search in PubMed,
EMBASE, the Cochrane Library, and www.clinicaltrials.gov
up to March 2018 to find systematic reviews, published and
unpublished RCTs, and nationally represented controlled
observational studies that reported adjusted effect estimates
(6,7). The data were extracted from the Clinical Trials
Transformation Initiative (https://www.ctti-clinicaltrials.
org/aact-database), checked for quality, and stored in
the High-Performance Computing Cluster platform
(https://hpccsystems.com).
We tested the null hypotheses of no differences in patient
outcomes after more versus less extensive blood pressure
lowering (6). We abstracted the information about study
population, interventions, comparators, and outcomes (6).

© Annals of Translational Medicine. All rights reserved.

Aronow and Shamliyan. Blood pressure in diabetes

We abstracted minimum datasets (e.g., number of the
subjects in treatment groups and events) to estimate
absolute risk difference, relative risk, and number needed to
treat for categorical variables (6). Statistical significance was
evaluated at a 95% confidence level (including the use of
P values).
We conducted a rapid review following the framework
of the AHRQ (8). We used the AHRQ recommended
methodological approach in the integration of existing
systematic reviews into our comprehensive synthesis of
evidence (9). Our goal was the integration of previously
published high quality reviews and consistent ranking of the
quality of evidence using GRADE methodology.
We performed meta-analyses when definitions of active
and control interventions and patient outcomes deem
similar (10). We examined consistency in results across
studies with chi-square tests and I2 statistics and concluded
statistically significant heterogeneity if I2 was >50% (6).
Statistically significant heterogeneity did not preclude
statistical pooling (10). However, we planned exploring
heterogeneity with a priori defined patient baseline
hypertensive status (10).
We defined harms as the totality of all possible adverse
consequences of an intervention.
We calculated absolute risk difference, number needed
to treat, and the number of attributable events based on
data from the published randomized trials, using STATA
software (StataCorp LP, College Station, TX, USA) (11).
Correction coefficients for zero events were used as
a default option, and intention to treat was used for
evidence synthesis (10). Superiority of interventions under
comparison was hypothesized (12). We used consensus
method guidelines for systematic review and meta-analyses
that do not recommend conducting post hoc analyses of
statistical power (13-15). Instead, we downgraded our
confidence in true treatment effects based on calculated
optimal information size as the number of patients required
for an adequately powered individual trial (16). Since power
is more closely related to number of events than to sample
size, we concluded imprecision in treatment effects if less
than 250 patients experienced the event (16).
We assessed reporting bias as a proportion of published
among all registered studies, unreported outcomes
compared with published protocols, or unreported
minimum data sets for reproducibility of the results (17).
We did not conduct formal statistical tests for publication
bias due to the questionable validity of such tests (18).
We evaluated the quality of the primary studies using
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the Cochrane risk of bias tool on a 3-point scale: high bias,
low bias, and unclear (6). We upgraded the risk of bias in
the body of evidence from low to high if at least 1 RCT
had high risk of bias (19,20). We defined indirectness in
outcomes from intermediate outcomes (21).
Treatment effect estimates were defined as precise when
pooled estimates had reasonably narrow 95% confidence
intervals (CI) and the number of events were greater than
250 (22). Justification of the sample size was not included in
grading of the evidence.
In assessing the quality of evidence in all studies, the
authors looked for the strength of association and evidence
of any reporting bias (23). The strength of the association
was evaluated, defining a priori a large effect when the
relative risk was greater than 2 and a very large effect when
the relative risk was greater than 5 (23). A small treatment
effect was construed when the relative risk was significant
but less than 2 (23).
The authors assigned the quality of evidence ratings as
high, moderate, low, or very low, according to risk of bias in
the body of evidence, directness of comparisons, precision
and consistency in treatment effects, and the evidence
of reporting bias, using Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
methodology (Supplementary file) (23). A high quality
of evidence was assigned to well-designed RCTs with
consistent findings. The quality of evidence was downgraded
to moderate if at least 1 of 4 quality of evidence criteria
were not met; for example, moderate quality of evidence
was assigned if there was a high risk of bias in the body of
evidence or if the results were not consistent or precise (23).
The quality of evidence was downgraded to low if 2 or more
criteria were not met.
A low quality of evidence was assigned to nonrandomized
studies and upgraded for the rating if there was a strong
association. Evidence was defined as insufficient when no
studies provided valid information about treatment effects.
This approach was applied regardless of whether the results
were statistically significant.
Results
Our comprehensive search in PubMed, EMBASE, the
Cochrane Library, and clinicaltrials.gov up to March 2018
retrieved 306 references and identified 16 publications of
systematic reviews and meta-analyses and 96 publications
of RCTs that enrolled adults primarily with type 2 diabetes
mellitus (Supplementary file, Figure S1). We excluded
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124 irrelevant references at the screening of the titles
and abstracts and 33 publications after full text review
because the studies did not address blood pressure targets
in patients with diabetes (Supplementary file, Figure S1).
Only 6 primary RCTs randomly assigned patients to lower
versus higher blood pressure targets and compared systolic
blood pressure (SBP) targets in patients with baseline
arterial hypertension (24,25) or diastolic blood pressure
(DBP) targets in patients with normal (26,27) or elevated
baseline blood pressure (28,29). All other RCTs compared
hypotensive drugs with placebo or with each other. Metaanalyses of such trials explored the association of baseline or
achieved blood pressure with patient outcomes (3-5,30-39).
In adults with diabetes and normal arterial blood
pressure, low-quality evidence suggests that there are no
differences in all-cause and cardiovascular mortality or
morbidity between intensive (10 mmHg below baseline
DBP) and moderate blood pressure control (DBP goal
80–89 mmHg; Table 1). Intensive blood pressure control
prevents cerebrovascular events and progression or
retinopathy in some patients (Table 1).
In adults with diabetes and elevated arterial blood
pressure (DBP ≥90 mmHg), low-quality evidence suggests
that there are no differences in all-cause and cardiovascular
mortality or stroke between intensive (DBP ≤85–75 mmHg)
and moderate blood pressure control (DBP goal
80–90 mmHg; Table 2). A single RCT suggests that a
reduction of DBP ≤80 mmHg results in a lower risk of
major cardiovascular events but higher risk of progressing
neuropathy (Table 2).
In adults with diabetes and elevated arterial blood
pressure (SBP 130–190 mmHg), moderate-quality
evidence suggests that there are no differences in allcause or cardiovascular mortality between intensive and
standard blood pressure control (Table 3 and Figure 1).
However, intensive blood pressure control decreases the
risk of diabetes-related mortality, fatal or nonfatal stroke
(Figure 2), prevalence of left ventricular hypertrophy and
electrocardiogram (ECG) abnormalities, macroalbuminuria,
and non-spine bone fractures (Table 3). A single RCT
(ACCORD) suggests that the risk of a composite outcome
(nonfatal myocardial infarction, nonfatal stroke, and death
from cardiovascular causes) is lower after intensive blood
pressure and good glycemic control but higher in adults with
poorly controlled diabetes (hemoglobin A1c >8.0; Table 3).
The benefits from intensive blood pressure control sustain
at 9 years of follow-up in older adults with 15% or greater
10-year coronary heart risk in the standard glucose control

atm.amegroups.com

Ann Transl Med 2018;6(11):199

Aronow and Shamliyan. Blood pressure in diabetes

Page 4 of 13

Table 1 The benefits and harms of intensive versus moderate diastolic blood pressure control in normotensive adults with diabetes mellitus
Outcome

Risk with intervention/
comparator per 1,000

Attributable avoided events
per 1,000 treated (95% CI)

Relative measure of association;
number needed to treat (95% CI)

No. of participants
(studies)

All-cause mortality**

63/65

NS

RR: 0.96 (0.53–1.75);
HR: 0.96 (0.53–1.75)

609 (2 RCTs) (26,27)

Cardiovascular
mortality*

55/37

NS

RR: 1.48 (0.65–3.40)

480 (1 RCT) (27,40)

Non-cardiovascular
mortality*

21/45

NS

RR: 0.47 (0.16–1.32)

480 (1 RCT) (27,40)

Cardiovascular
event**

73/56

NS

RR: 1.31 (0.71–2.42)

609 (2 RCTs) (26,27)

Congestive heart
failure*

51/45

NS

RR: 1.12 (0.50–2.49)

480 (1 RCT) (27,40)

Myocardial
infarction*

80/62

NS

RR: 1.30 (0.68–2.49)

480 (1 RCT) (27,36)

Cerebrovascular
accident*

17/53

37 [4–69]

RR: 0.32 (0.10–0.95);
NNTp: 27 [14–255]#

480 (1 RCT) (27,36)

Retinopathy
progression**

269/369

NR

RR: 0.74 (0.60–0.93)#

609 (2 RCTs) (26,27)

Neuropathy
progression**

349/337

NS

RR: 1.04 (0.83–1.29)

609 (2 RCTs) (26,27)

Population: adults with diabetes and normal arterial blood pressure; Settings: outpatient; Intervention: intensive blood pressure control
(10 mmHg below baseline DBP); Comparator: moderate blood pressure control (DBP goal 80–89 mmHg). #, favors lower blood pressure
target; *, very low quality evidence; **, low quality evidence. CI, confidence interval; DBP, diastolic blood pressure; GRADE, Grading of
Recommendations Assessment, Development and Evaluation; HR, hazard ratio; NNTp, number needed to treat to prevent an outcome in
one patient; RCT, randomized controlled trial; RR, relative risk; NS, no statistically significant difference; NR, not reported.

arm of ACCORD trial (Table 3). The same study reported
an increased risk of adverse effects from hypotensive
medications, including hypotension or hyperkalemia, after
intensive blood pressure control (Table 3).
Primary studies did not address circadian fluctuations in
blood pressure or the risk of orthostatic hypotension after
intensive versus standard blood pressure targets. For the
record, the ACCORD study found no differences in patient
falls or trauma after intensive blood pressure control (Table 3).
Published meta-analyses of aggregate data from RCTs
aimed at efficacy or comparative effectiveness of specific
hypotensive drugs in adults with comorbid diabetes and
arterial hypertension (baseline blood pressure >150 mmHg)
agree that attained SBP 130–139 and DBP 75–80 mmHg
is associated with lower risk of all-cause mortality and
stroke (Table S1) (5,31,33,37). Systematic reviews and
guidelines vary in determining the balance between benefits
and harms of lowering blood pressure below 130 mmHg
(4,5). We looked at the pooled relative risk of all reported
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outcomes in published reviews (Table S1) and found 2 metaanalyses that reported a statistically significant increase
in the risk of cardiovascular mortality in association with
lower baseline blood pressure (Table S2) (31,37). Antihypertensive treatments are associated with a higher risk of
cardiovascular mortality per each 10 mmHg lower baseline
SBP and DBP (Table S2).
Discussion
Our review found moderate direct quality evidence that
in adults with diabetes and elevated SBP, intensive blood
pressure control (target SBP <120–140 mmHg) decreases
the risk of diabetes-related mortality, fatal or nonfatal
stroke, prevalence of left ventricular hypertrophy and ECG
abnormalities, macroalbuminuria, and non-spine bone
fractures, with no differences in all-cause or cardiovascular
mortality or falls.
We downgraded the quality of evidence due to risk
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Table 2 The benefits and harms of intensive versus moderate diastolic blood pressure control in adults with diabetes mellitus and arterial
hypertension
Outcome

Risk with intervention/
comparator per 1,000

Attributable avoided events
per 1,000 treated (95% CI)

Relative measure of association;
number needed to treat (95% CI)

No. of participants
(studies)

All-cause mortality**

45/71

NS

RR: 0.63 (0.38–1.05)

1,971 (2 RCTs)
(28,29,40)

Cardiovascular
mortality**

27/44

NS

RR: 0.63 (0.39–1.03)

1,971 (2 RCTs)
(28,29,40)

Congestive heart
failure*

38/39

NS

RR: 0.98 (0.40–2.43)

470 (1 RCT)
(28,40)

Major cardiovascular
events, DBP ≤80*

44/90

Avoided 46 [15–77]

RR: 0.49 (0.30–0.80);
NNTp: 22 [13–67]#

1,000 (1 RCT) (29)

Major cardiovascular
events, DBP ≤85*

68/90

NS

RR: 0.76 (0.49–1.16)

1,002 (1 RCT) (29)

Any cardiovascular
event*

63/60

NS

RR: 1.05 (0.52–2.13)

470 (1 RCT)
(28,41)

Myocardial
infarction*

25/38

NS

RR: 0.78 (0.38–1.61)

1,971 (2 RCTs)
(28,40)

Stroke**

27/35

NS

RR: 0.81 (0.49–1.33)

1,971 (2 RCTs)
(28,29,40)

Neuropathy
progression*

400/310

Excessive 92 [6–178]

RR: 1.30 (1.01–1.66);
NNT: 11 [6–174]†

470 (1 RCT) (28)

Retinopathy
progression*

300/340

NS

RR: 0.88 (0.68–1.15)

470 (1 RCT) (28)

Population: adults with diabetes and elevated arterial blood pressure (DBP ≥90 mmHg); Settings: outpatient; Intervention: intensive blood
pressure control (DBP ≤75–85 mmHg); Comparator: moderate blood pressure control (DBP goal 80–90 mmHg). #, favors lower blood
pressure target; †, favors higher blood pressure target; *, very low quality evidence; **, low quality evidence. CI, confidence interval; DBP,
diastolic blood pressure; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NNT, number needed to treat;
NNTp, number needed to treat to prevent an outcome in one patient; RCT, randomized controlled trial; RR, relative risk.

of bias, small number of events in the studies, and
heterogeneity in treatment effects across the studies. We
did not conduct meta-regression of few RCTs that directly
compared patient outcomes after intensive versus standard
blood pressure targets (6). Instead, we reviewed published
meta-analyses of RCTs aimed at comparative effectiveness of
blood lowering drugs in adults with diabetes that concluded
no benefits from lowering blood pressure below 130 mmHg.
Such publications employed meta-regression of aggregated
data that can generate hypotheses of potential harms from
extensive lowering blood pressure control specifically
in adults with normal baseline blood pressure (45).
Published meta-analyses that included the data from the
Systolic Blood Pressure Intervention Trial (SPRINT)
suggest similar reduction in the risk of major cardiovascular
events from intensive blood pressure lowering in adults

© Annals of Translational Medicine. All rights reserved.

with and without diabetes (20,38,46). Individual rather than
aggregate patient data meta-analyses would provide better
evidence about the association between specific drugs,
baseline and achieved blood pressure, and patient outcomes
independent of drug effects (47).
We found no studies that addressed the risk of
hospitalization or long-term quality of life in relation to blood
pressure targets in adults with diabetes. Although orthostatic
hypotension is associated with poor patient outcomes,
the evidence regarding the risk of this complication after
intensive or standard blood pressure control is insufficient
(3,48,49). Primary studies and meta-analyses did not discuss
the importance of pulse pressure in reducing morbidity and
mortality in adults with diabetes (50).
Guidelines recommend healthy diet, weight normalization,
and physical activity for all adults with diabetes (Table S3) (51-58).
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Table 3 The benefits and harms of intensive versus standard systolic blood pressure control in adults with diabetes mellitus and arterial
hypertension
Attributable avoided
events per 1,000
treated (95% CI)

Relative measure of
association; number
needed to treat (95% CI)

No. of participants
(studies)

91/82

NS

RR: 0.94 (0.75–1.18)

5,881 (2 RCTs) (25,36)

All-cause mortality, 9 years of
follow-up*

224/234

NS

RR: 0.96 (0.78–1.17)

1,284 (1 RCT) (42)

Cardiovascular death, nonfatal MI,
nonfatal stroke, 9 years of followup*

199/259

Avoided 60 [14–106]

RR: 0.77 (0.63–0.94);
NNTp: 17 [9–70]#

1,284 (1 RCT) (42)

Coronary death, nonfatal MI,
unstable angina, 9 years of followup*

201/267

Avoided 66 [20–113]

RR: 0.75 (0.62–0.92);
NNTp: 15 [9–49]#

1,284 (1 RCT) (42)

Outcome
All-cause mortality***

Risk with
intervention/
comparator per 1,000

Cardiovascular death, 9 years of
follow-up*

58/76

NS

RR: 0.77 (0.51–1.16)

1,284 (1 RCT) (42)

Fatal myocardial infarction**

21/17

NS

RR: 0.80 (0.50–1.28)

5,882 (2 RCTs) (24,25)

NR

#

RR: 0.41 (0.20–0.84)

5,882 (2 RCTs) (24,25)

Fatal stroke**

4/7

Any stroke**

24/35

Avoided 16 [7–24]

RR: 0.58 (0.43–0.78);
NNTp: 63 [42–143]#

5,881 (2 RCTs) (25,36)

Nonfatal stroke**

20/29

Avoided 12 [4–20]

RR: 0.60 (0.43–0.83);
NNTp: 83 [50–250]#

5,882 (2 RCTs) (24,25)

Nonfatal myocardial infarction**

57/63

NS

RR: 0.87 (0.71–1.07)

5,882 (2 RCTs) (24,25)

Non-fatal MI, 9 years of followup*

100/147

Avoided 47 [12–83]

RR: 0.68 (0.50–0.91);
NNTp: 21 [12–87]#

1,284 (1 RCT) (42)

Myocardial infarction, any***

115/123

NS

RR: 0.90 (0.78–1.04)

5,881 (2 RCTs) (25,36)

Cancer death**

23/19

NS

RR: 1.17 (0.74–1.84)

5,882 (2 RCTs) (24,25)

Fatal or nonfatal heart failure*

33/41

NS

RR: 0.67 (0.34–1.36)

5,882 (2 RCTs) (24,25)

MACE**; subgroup: HbA1c ≤8.0

444/489

Avoided 45 [17–73]

RR: 0.91 (0.85–0.97);
NNTp: 22 [14–61]#

4,734 (1 RCT) (24)

MACE**; subgroup: HbA1c >8.0

554/507

Excessive 47
[19–76]

RR: 1.09 (1.04–1.15);
NNT: 21 (53–13)†

4,734 (1 RCT) (24)

Mortality due to congestive heart
failure*

5/4

NS

RR: 1.10 (0.47–2.59)

4,734 (1 RCT) (24)

Mortality due to fatal arrhythmia*

1/1

NS

RR: 1.00 (0.14–7.12)

4,734 (1 RCT) (24)

Avoided 51 [8–93]

RR: 0.68 (0.50–0.92);
NNTp: 20 [11–120]#

1,148 (1 RCT) (25)

Excessive 20
[11–28]

RR: 2.58 (1.70–3.91);
NNT: 50 [35–87]†

4,733 (1 RCT) (24)

Avoided 55 [5–105]

RR: 0.76 (0.60–0.96);
NNTp: 18 [10–182]#

1,148 (1 RCT) (25)

Mortality related to diabetes*

108/159

Adverse Events from bloodpressure medications*

33/13

Abnormal Q waves in ECG*

175/231

Table 3 (continued)
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Table 3 (continued)
Outcome

Risk with
intervention/
comparator per 1,000

Attributable avoided
events per 1,000
treated (95% CI)

Relative measure of
association; number
needed to treat (95% CI)

No. of participants
(studies)

Abnormal Q, ST, or T waves in
ECG*

38/77

Avoided 39 [9–68]

RR: 0.50 (0.30–0.82);
NNTp: 26 [15–112]#

1,148 (1 RCT) (25)

Angina*

59/56

NS

RR: 1.05 (0.64–1.73)

1,148 (1 RCT) (25)

Left ventricular hypertrophy*

17/30

Avoided 13 [4–22]

RR: 0.58 (0.39–0.86);
NNTp: 79 [46–273]#

4,331 (1 RCT) (43)

Avoided 94 [35–154]

RR: 0.78 (0.67–0.91);
NNTp: 11 [6–29]#

1,148 (1 RCT) (25)

Any diabetes-related end point**

342/436

Macroalbuminuria**

56/78

NR

RR: 0.77 (0.63–0.94)#

5,527 (2 RCTs) (24,25)

Microalbuminuria***

253/296

NS

RR: 0.92 (0.85–1.01)

5,527 (2 RCTs) (24,25)

4/3

NS

RR: 1.38 (0.18–10.81)

5,881 (2 RCTs) (24,25)

Peripheral vascular disease*

11/21

NS

RR: 0.51 (0.19–1.36)

1,148 (1 RCT) (25)

Cataract extraction*

47/36

NS

RR: 1.32 (0.72–2.42)

1,148 (1 RCT) (25)

Vision preventing driving *

42/62

NS

RR: 0.69 (0.41–1.15)

1,148 (1 RCT) (25)

Vitreous hemorrhage*

4/13

NS

RR: 0.31 (0.07–1.29)

1,148 (1 RCT) (25)

200/206

NS

RR: 0.97 (0.84–1.11)

3,099 (1 RCT) (44)

Fatal accident*

1/3

NS

RR: 0.51 (0.03–8.20)

1,148 (1 RCT) (25)

Fatal accident/trauma*

2/1

NS

RR: 2.51 (0.49–12.92)

4,734 (1 RCT) (24)

Renal failure*

Falls*

All non-spine bone fractures*

76/98

Avoided 23 [3–43]

RR: 0.77 (0.61–0.97);
NNTp: 44 [23–337]#

3,099 (1 RCT) (44)

Ankle fractures*

16/24

NS

RR: 0.67 (0.41–1.11)

3,099 (1 RCT) (44)

Distal forearm fractures*

8/8

NS

RR: 0.94 (0.43–2.06)

3,099 (1 RCT) (44)

Foot fractures*

6/13

NS

RR: 0.46 (0.21–1.01)

3,099 (1 RCT) (44)

Hip fractures*

3/8

NS

RR: 0.43 (0.15–1.20)

3,099 (1 RCT) (44)

Proximal humerus fractures*

10/12

NS

RR: 0.81 (0.41–1.58)

3,099 (1 RCT) (44)

Hives or swelling*

88/88

NS

RR: 1.00 (0.67–1.51)

969 (1 RCT) (24)

Hyperkalemia*

4/0

Excessive 3 [1–6]

RR: 9.03 (1.15–71.25);
NNT: 295 [166–1,299]†

4,733 (1 RCT) (24)

Hypotension*

7/0

Excessive 7 [3–10]

RR: 17.06 (2.27–128.12);
NNT: 148 [97–306]†

4,733 (1 RCT) (24)

Population: adults with diabetes and elevated arterial blood pressure (SBP: 130–190 mmHg); Settings: outpatient; Intervention: intensive
blood pressure control [target SBP <120 versus <140 mmHg in ACCORD study and 144/82 versus 154/87 mmHg in UKPDS 38 (66)
study]; Comparator: standard blood pressure control. *, very low quality evidence; **, low quality evidence; ***, moderate quality evidence;
#
, favors lower blood pressure target; †, favors higher blood pressure target; CI, confidence interval; ECG, electrocardiogram; GRADE,
Grading of Recommendations Assessment, Development and Evaluation; NNT, number needed to treat; NNTp, number needed to treat
to prevent an outcome in one patient; RCT, randomized controlled trial; RR, relative risk; SBP, systolic blood pressure; MACE, major
cardiovascular events including nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes.
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Figure 1 Cardiovascular outcomes after intensive versus standard systolic blood pressure control in adults with diabetes mellitus and arterial
hypertension. Target systolic blood pressure <120 versus <140 mmHg in ACCORD study and 144/82 versus 154/87 mmHg in UKPDS 38
study. RR, relative risk.

Figure 2 Stroke after intensive versus standard systolic blood pressure control in adults with diabetes mellitus and arterial hypertension.
Target systolic blood pressure <120 versus <140 mmHg in ACCORD study and 144/82 versus 154/87 mmHg in UKPDS 38 study.
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In addition to healthy lifestyle, recent guidelines
recommend antihypertensive drug treatments in patients
with diabetes and baseline blood pressure ≥130/80 mmHg
(54-56,59-61). The American Heart Association
recommends a treatment goal of <130/80 mmHg, while the
American Diabetes Association recommends a treatment
goal of <140/90 mmHg with lower targets in individuals
at high risk of cardiovascular disease (54-56,59-61).
Other guidelines also recommend baseline cardiovascular
disease risk assessment and evaluation of kidney, eye, or
cerebrovascular damage in determining individual treatment
goals (51,62-65). The American Geriatrics Society
guidelines acknowledge the potential harm from arterial
hypotension in older adults with diabetes mellitus (66).
Guidelines generally agree that high quality care for
patients with diabetes include normalization of HbA1C
without hypoglycemia (67-69). This definition of high
quality care for patients with diabetes should include
normalization of blood pressure including pulse pressure
without hypotension.
Regardless of the intended blood pressure goal, the
ability to maintain a lower blood pressure threshold in
a real-world setting outside of a controlled trial is an
important disease management consideration (70). It is
often reported that more than half of treated patients
are not able to maintain blood pressure control, even at
a threshold of <140/85 mmHg (71). Findings from the
DIALOGUE study (72), a multicenter prospective registry
among patients with hypertension and type II diabetes,
demonstrated that patients with a “strict” SBP target
(≤130 mmHg) had more contacts with general practitioners
than any other patient group. In addition, among patients
with a lower blood pressure target, only half actually
maintained this threshold over 6 months. More specifically,
53% of patients in the “strict” target group (≤130 mmHg)
were able to maintain this blood pressure goal over
time, and 55% of patients in the “medium” target group
(130 to ≤135 mmHg) were able to do so.
The majority of the studies relied on office measurements
of blood pressure rather than ambulatory blood pressure
monitoring. However, ambulatory blood pressure
monitoring improves baseline and post-treatment risk
assessment (73-86). Evidence-based guidelines recommend
ambulatory blood pressure monitoring for diagnosis and
individualization of treatment goals in adults with arterial
hypertension (51,56,87-89).
Our review has several limitations. We analyzed direct
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evidence from RCTs that randomly assigned patients to
more versus less intensive blood pressure goals and did
not abstract the data from RCTs aimed at efficacy or
comparative effectiveness of hypotensive drugs. We could
not reproduce the results from meta-regression, because
the authors did not provide sufficient data (30,33,35-38,90).
We did not contact authors of meta-analyses requesting
reproducible data. We do not know how many unregistered
and unpublished studies analyzed the association between
baseline and attained blood pressure and patient outcomes.
Despite this limitation, we present conflicting evidence
from all published and unpublished studies appraised with
consistent GRADE methodology. In contrast with previous
meta-analyses of direct evidence, we grouped studies by
baseline hypertension status and by targeted diastolic and
SBP targets (38,40).
Our review has implications for clinical practice.
Clinicians should assess baseline cardiovascular risk,
recommend behavioural and pharmacological treatments
aiming at blood pressure normalization without
hypotension or orthostatic hypotension (91). They should
engage patients in life style optimization, blood pressure
self-monitoring, and monitoring of drug adverse effects (92).
Our review has policy implications. High quality care in
patients with diabetes and arterial hypertension should be
defined as achievement of normal blood pressure without
episodes of hypotension and with minimal risk of orthostatic
hypotension or other serious harms from recommended drugs.
Our review has research implications. Future research
should determine the optimal blood pressure targets in
subpopulations with diabetes and various demographic,
socioeconomic, and behavioral factors, as well as
comorbidities. Composite outcomes should be avoided.
Trials should use blood pressure monitoring and examine
pulse pressure, the risk of orthostatic hypotension and other
drug-related harms in determining optimal choice of drugs
and blood pressure targets in individual patients.
Conclusions
Based on our review, we conclude that in adults with
diabetes and arterial hypertension, in order to reduce
the risk of stroke, left ventricular hypertrophy and ECG
abnormalities, macroalbuminuria, and non-spine bone
fractures, clinicians should encourage healthy lifestyle
choices and antihypertensive medications targeting blood
pressure of 120–130/80 mmHg, with close monitoring of

atm.amegroups.com

Ann Transl Med 2018;6(11):199

Aronow and Shamliyan. Blood pressure in diabetes

Page 10 of 13

daily blood pressure fluctuations, episodes of orthostatic
hypotension, and other drug-related harms.
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Supplementary

PICO question this report is addressing:
What are the benefits and harms of “lower” blood
pressure targets compared to “standard” blood pressure
targets in high-risk diabetic patients?
Population

Adults with type 2 diabetes
Baseline blood pressure
Patient demographics, socioeconomic status,
smoking, physical activity, diet (sodium intake),
prior treatment and response to medications
for hypertension, comorbidities (e.g., cardiac
arrhythmias, obesity, diabetes, asthma, chronic
obstructive pulmonary disease), concomitant
and concurrent medications

Intervention

Inclusion criteria
Participants

Adults with type 2 diabetes

Language restrictions

English

Publication dates (from and to)
for searching

2010–2018 (published highquality reviews should
address early publications
of randomized trials)

Inclusion of guidelines

ECRI institute (formerly the
“Emergency Care Research
Institute”) appraised,
published since 2010

Lower blood pressure targets as defined in the
studies

Comparator

Higher blood pressure targets as defined in the
studies

Primary
outcome(s)

All-cause mortality

Setting

Study eligibility

Meeting Institute of
Medicine criteria for
trustworthy guidelines
Inclusion of clinical performance
measures

Yes
Yes

All adverse events

Inclusion for systematic reviews
(review quality, reviews with
quantitative analyses)

Outpatient

Inclusion of randomized trials

Yes, published since 2010

Inclusion of observational studies
for harms (study characteristics,
design, applicability, sample size,
statistical methods to reduce
bias)

Nationally representative
prospective cohort studies
of adverse effects with
multivariate adjustment of
adverse effects

Cardiovascular disease (CVD) events (stroke,
myocardial infarction) and mortality

Exclusion criteria
Interventions

We exclude trials of interventions at adults
without diabetes

Outcomes

Intermediate outcomes such as hemodynamic
characteristics

Study design

Uncontrolled case series or uncontrolled
clinical trials
Meeting abstracts presenting the results of
randomized controlled trials (RCT) that have
been published in peer-reviewed journals or
have results in clinicaltrials.gov

Search strategy
The medical librarian develops specific search strategies
based on the PICOs formulated by our clinical and
epidemiology staff. We search for all relevant articles
published in English from 2010 up to March 2018 in
PubMed, EMBASE, and the Cochrane Library. To identify
grey unpublished data, we conduct a search of the trial
registry clinicaltrials.gov.
We conduct the following searches:
PubMed searches for:
(I) RCTs;
(II) Observational studies of harms (multivariate
adjusted estimates from nationally representative
cohorts or administrative databases) (6,7);
(III) Clinical practice guidelines.
EMBASE searches for full publications of:
(I) RCTs;
(II) Observational studies (multivariate adjusted
estimates from nationally representative cohorts or
administrative databases).
The bibliographies of identified articles are scanned, and
study investigators are contacted for additional publications.
Study selection
The study epidemiologist and an author-subject matter
expert contribute equally to resolving differences and decide
the determination of eligibility collaboratively.
The study epidemiologist and an author-subject matter
expert determine eligibility for full text review, first screen
title, and abstracts. All citations found during the searches
are stored in a reference database.

Data extraction and strategy for data synthesis
Data extraction
T h e d a t a w a s e x t r a c t e d f r o m t h e C l i n i c a l Tr i a l s
Transformation Initiative (https://www.ctti-clinicaltrials.
org/aact-database), checked for quality, and stored in the
HPCC platform (High-Performance Computing Cluster,
https://hpccsystems.com/).
We manually abstracted the data from published
articles into the abstraction form. We checked the data for
ambiguity (i.e., data reported in percentiles conflicting with
unit data and vice versa; values outside a normal range) and
mismatch with the published data. Identified errors have
been discussed and corrected.
We abstract the information about study population,
interventions, comparators, and outcomes. We abstract
minimum datasets (e.g., number of the subjects in treatment
groups and events) to estimate absolute risk difference, relative
risk, and number needed to treat for categorical variables.
Means and standard deviations of continuous variables, e.g.,
total scores from the quality of life scales are abstracted. Statistical
significance is evaluated at a 95% confidence level (including the
use of P values). All authors have access to the data.
We conduct an overview of the reviews following the
framework of the Cochrane Collaboration. We perform metaanalyses or update published meta-analyses. Pooling criteria
include the exact same definitions of the active and control
intervention, patient outcomes, and similar follow-up time (10).
We define harms as the totality of all possible adverse
consequences of an intervention. Investigators sometimes
defined harmful effects as unrelated to examined treatments.
Harms are analyzed regardless of how investigators related
them to treatments.
We calculate absolute risk difference, number needed
to treat, and the number of attributable events based on
data from the published randomized trials, using STATA
software. Correction coefficients for zero events are used as
a default option in both software programs, and intention
to treat is used for evidence synthesis. Superiority of
interventions under comparison is hypothesized.
We assess reporting bias as a proportion of published
among all registered studies, unreported outcomes
compared with published protocols, or unreported
minimum data sets for reproducibility of the results. We did
not conduct formal statistical tests for publication bias due
to the questionable validity of such tests (18).

To examine the role of patient characteristics, a search is
undertaken for subgroup analyses by patient demographics,
baseline and achieved blood pressure, prior treatment
response, and comorbidities in systematic reviews and
randomized trials, including significant interaction effects.
Methodological assessment of the included studies
For systematic reviews (QIRs), we use the Assessment of
Multiple Systematic Reviews (AMSTAR) scale to determine
the methodological strength of the systematic reviews (99).
For randomized studies, we apply the Cochrane risk of
bias tool. Risk of bias is assessed on a 3-point scale: high
bias, low bias, and unclear (100,101). A low risk of bias
is assumed when RCTs met all the risk-of-bias criteria, a
medium risk of bias if at least 1 of the risk-of-bias criteria
is not met, and a high risk of bias if 2 or more risk-of-bias
criteria are not met. An unknown risk of bias is assigned for
the studies with poorly reported risk-of-bias criteria. We
assign high risk of bias to all observational studies.
For clinical practice guidelines, we use the Appraisal of
Guidelines for Research and Evaluation (AGREE) II (2009)
tool, which covers 23 items in 6 domains and 2 overall
global ratings (102,103).
Quality assessment of the included studies and
the body of evidence by outcome according to
the GRADE framework
The authors assign the quality of evidence ratings as high,
moderate, low, or very low, according to risk of bias in the
body of evidence, directness of comparisons, precision and
consistency in treatment effects, and the evidence of reporting
bias, using Grading of Recommendations Assessment,
Development and Evaluation (GRADE) methodology (23).
We upgrade the risk of bias from low to high if at least 1 RCT
had high risk of bias. We define indirectness in outcomes from
intermediate outcomes. We review published network metaanalyses but do not conduct indirect comparisons.
Treatment effect estimates are defined as precise when pooled
estimates have reasonably narrow 95% confidence intervals and
the number of events are greater than 250. Justification of the
sample size is not included in grading of the evidence. We do
not conduct post hoc statistical power analyses.
In assessing the quality of evidence in all studies, the
authors look for a dose response association, the strength
of association, and evidence of any reporting bias. The
strength of the association is evaluated, defining a priori a
large effect when the relative risk is greater than 2 and a
very large effect when the relative risk is greater than 5. A

small treatment effect is construed when the relative risk
was significant but less than 2. For standardized continuous
measures of secondary and intermediate outcomes, the
magnitude of the effect is defined according to Cohen et al.
as small, moderate, and large, corresponding to mean
differences in standard deviation units of 0 to 0.5, 0.5 to 0.8,
and greater than 0.8, respectively.
A high quality of evidence is assigned to well-designed RCTs
with consistent findings. The quality of evidence is downgraded
to moderate if at least 1 of 4 quality of evidence criteria is not
met; for example, moderate quality of evidence is assigned if
there was a high risk of bias in the body of evidence or if the
results are not consistent or precise. The quality of evidence is
downgraded to low if 2 or more criteria are not met.
A low quality of evidence is assigned to nonrandomized
studies and upgraded for the rating if there was a strong
or dose-response association. Evidence is defined as
insufficient when no studies provided valid information
about treatment effects. This approach is applied regardless
of whether the results were statistically significant.
The authors assign strength of the recommendations
based on overall quality of evidence, balances between
benefits and harms, healthcare consumers’ and clinicians’
values and preferences, and cost-effectiveness studies using
the GRADE methodology.
Grade

Definition

High

We are very confident that the estimate of effect lies
close to the true effect for this outcome. The body of
evidence has few or no deficiencies. We believe that
the findings are stable, i.e., another study would not
change the conclusions

Moderate

We are moderately confident that the estimate of effect
lies close to the true effect for this outcome. The body
of evidence has some deficiencies. We believe that the
findings are likely to be stable, but some doubt remains

Low

We have limited confidence that the estimate of effect
lies close to the true effect for this outcome. The body
of evidence has major or numerous deficiencies (or
both). We believe that additional evidence is needed
before concluding either that the findings are stable or
that the estimate of effect is close to the true effect

Very low

We have very little confidence in the effect estimate:
the true effect is likely to be substantially different from
the estimate of the effect. Any estimate of effect is very
uncertain

Insufficient

We have no evidence, we are unable to estimate an
effect, or we have no confidence in the estimate of
effect for this outcome. No evidence is available or
the body of evidence has unacceptable deficiencies,
precluding reaching a conclusion

PubMed search of record:
(((((((((((((((diabet*[Title/Abstract]) OR "Diabetes
Mellitus/drug therapy"[Majr])) AND (((((hypertensi*[Title/
Abstract]) OR (( "Blood Pressure/drug effects"[Mesh]
OR "Blood Pressure/pharmacology"[Mesh] OR "Blood
Pressure/therapy"[Mesh] ))) OR (((("systolic blood
pressure"[Title/Abstract]) OR "systolic pressure"[Title/
A b s t r a c t ] ) O R " d i a s t o l i c b l o o d p r e s s u r e " [ Ti t l e /
Abstract]) OR "diastolic pressure"[Title/Abstract])) OR
normotensive[Title/Abstract]) OR "Hypertension/drug
therapy"[Majr]))) AND ((((((strict*[Title/Abstract]) OR
target*[Title/Abstract]) OR tight*[Title/Abstract]) OR
intens*[Title/Abstract]) OR below[Title/Abstract]) OR
moderat*[Title/Abstract])))) AND (((((("Antihypertensive
Agents"[Mesh]) OR "Antihypertensive Agents"
[Pharmacological Action]) OR "Angiotensin II Type 1
Receptor Blockers"[Mesh])) OR antihypertensive[Title/
Abstract]) OR "angiotensin II"[Title/Abstract]))) NOT
((((((("Letter"[Publication Type]) OR "News"[Publication
Type]) OR "Patient Education Handout"[Publication
Ty p e ] ) O R " C o m m e n t " [ P u b l i c a t i o n Ty p e ] ) O R
" E d i t o r i a l " [ P u b l i c a t i o n Ty p e ] ) ) O R " N e w s p a p e r
Article"[Publication Type]))) NOT (("Animals"[Mesh])
NOT (("Animals"[Mesh]) AND "Humans"[Mesh]))))
AND (((((((((random*[Title/Abstract]) OR placebo*[Title/
Abstract]) OR "double blind"[Title/Abstract]) OR "triple
blind"[Title/Abstract]) OR prospective[Title/Abstract])
OR multicenter[Title/Abstract])) OR "Multicenter Study"
[Publication Type]) OR "Randomized Controlled Trial"
[Publication Type:NoExp])))
PubMed search of record for CPGs:
(((((((((((diabet*[Title/Abstract]) OR "Diabetes Mellitus/
drug therapy"[Majr])) AND (((((hypertensi*[Title/Abstract])
OR (( "Blood Pressure/drug effects"[Mesh] OR "Blood
Pressure/pharmacology"[Mesh] OR "Blood Pressure/
therapy"[Mesh] ))) OR (((("systolic blood pressure"[Title/
Abstract]) OR "systolic pressure"[Title/Abstract]) OR
"diastolic blood pressure"[Title/Abstract]) OR "diastolic
pressure"[Title/Abstract])) OR normotensive[Title/
Abstract]) OR "Hypertension/drug therapy"[Majr]))) AND
((((((strict*[Title/Abstract]) OR target*[Title/Abstract])
OR tight*[Title/Abstract]) OR intens*[Title/Abstract]) OR
moderat*[Title/Abstract])))) AND (((((("Antihypertensive
Agents"[Mesh]) OR "Antihypertensive Agents"
[Pharmacological Action]) OR "Angiotensin II Type 1
Receptor Blockers"[Mesh])) OR antihypertensive[Title/
Abstract]) OR "angiotensin II"[Title/Abstract]))) AND

(((((((((((((((((((((((("Guideline"[Publication Type]) OR
"Practice Guideline"[Publication Type])) OR "Consensus
Development Conference"[Publication Type]) OR
"Consensus Development Conference, NIH"[Publication
Type]) OR "Practice Guideline"[Publication Type]) OR
"Guideline"[Publication Type]) OR ((clinical[Title])
AND guideline*[Title])) OR (((clinical*[Title]) AND
guide*[Title]) AND manage*[Title])) OR ((best[Title])
A N D p r a c t i c e * [ Ti t l e ] ) ) O R ( ( e v i d e n c e [ Ti t l e ] )
A N D s y n t h e s * [ Ti t l e ] ) ) O R ( ( c o n s e n s u s [ Ti t l e ] )
AND develop*[Title])) OR ((practice[Title]) AND
guideline*[Title])) OR (("evidence based"[Title])
A N D g u i d e l i n e * [ Ti t l e ] ) ) O R ( ( c o n s e n s u s [ Ti t l e ] )
AND statement*[Title])) OR ((committee[Title])
AND opinion*[Title])) OR ((practice[Title])
AND bulletin*[Title])) OR ((clinical[Title]) AND
recommendation*[Title])) OR ((("U.S. Preventive
Services Task Force"[Title/Abstract]) OR USPSTF[Title/
Abstract]) OR "United States Preventive Services Task
Force"[Title/Abstract])) OR ACR Appropriateness
Criteria[Title])) NOT ((((((("Letter"[Publication Type])
OR "News"[Publication Type]) OR "Patient Education
Handout"[Publication Type]) OR "Comment"[Publication
Type]) OR "Editorial"[Publication Type])) OR "Newspaper
Article"[Publication Type]))) NOT (("Animals"[Mesh])
NOT (("Animals"[Mesh]) AND "Humans"[Mesh])))))
Embase
No.
Query
Results
273
#64
#53 AND #63
2,015,375
#63
#54 OR #56 OR #57 OR #58 OR #59 OR #62
1,509,234
#62
#61 OR 'double blind procedure'/de OR 'multicenter
study'/de OR 'prospective study'/de OR 'randomized
controlled trial'/de
1,130,198
#61

random*:ab,ti OR placebo*:ab,ti OR (double NEXT/1
blind):ab,ti OR (triple NEXT/1 blind):ab,ti

#45 NOT #46

33,224

#46

#59

'letter'/de OR 'editorial'/de OR 'note'/de OR 'conference
paper'/de OR 'short survey'/exp OR 'conference
abstract'/it

'hazard ratio'/de
53,805
#58
'proportional hazards model'/de
151,708
#57
nation*:ab,ti OR registr* AND cohort OR 'cox
regression':ab,ti OR 'hazard ratio':ab,ti

5,188,835

2,124
#45
#43 AND #44
671,989
#44

274,206

#1 OR #3 OR #4

#56

14,384

'multivariate analysis'/exp

#43

324,727

multivar*:ab,ti

#16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR
#23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR
#30 OR #31 OR #32 OR #33OR #34 OR #36 OR #37 OR
#38 OR #41 OR #42

638

19

#53

#42

#14 AND #52

(aggressive NEAR/3 systolic):ab,ti

1,471

4

#52

#41

#47 NOT #51

(aggressive NEAR/3 diastolic):ab,ti

4,776,528

464

#51

#38

#48 NOT #50

(below NEAR/3 systolic):ab,ti

15,578,685

352

#50

#37

#48 AND #49

(below NEAR/3 diastolic):ab,ti

15,578,685

214

#49

#36

'human'/exp

(intensi* NEAR/3 systolic):ab,ti

20,265,320

81

#48

#34

'animal'/exp

(intensi* NEAR/3 diastolic):ab,ti

1,488

12

#47

#33

#54

(tight* NEAR/3 diastolic):ab,ti

#20

23

(below NEAR/3 pressure):ab,ti

#32

1,492

(tight* NEAR/3 systolic):ab,ti

#19

17

(intensi* NEAR/3 pressure):ab,ti

#31

452

(strict* NEAR/3 systolic):ab,ti

#18

4

(tight* NEAR/3 pressure):ab,ti

#30

420

(strict* NEAR/3 diastolic):ab,ti

#17

208

(strict* NEAR/3 pressure):ab,ti

#29

3,756

(target* NEAR/3 diastolic):ab,ti

#16

403

(target* NEAR/3 pressure):ab,ti

#28

117,953

(target* NEAR/3 systolic):ab,ti

#14

522

#12 OR #13

#27

53,840

(moderate NEAR/3 systolic):ab,ti

#13

451

antihypertensive:ab,ti

#26

78,644

(moderate NEAR/3 diastolic):ab,ti

#12

161

'antihypertensive agent'/exp/mj/dd_dt

#25

504,814

(standard NEAR/3 diastolic):ab,ti

#9

324

hypertensi*:ab,ti

#24

61,009

(standard NEAR/3 systolic):ab,ti

#8

1,635

'hypertension'/exp/mj/dm_dt

#23

83,927

(standard NEAR/3 pressure):ab,ti

#4

1,226

#3 AND 'drug therapy'/lnk

#22

664,883

(moderate NEAR/3 pressure):ab,ti

#3

394

diabet*:ab,ti

#21

74,733

(aggressive NEAR/3 pressure):ab,ti

#1

3,343

'diabetes mellitus'/exp/mj/dm_dt

306 references were identified
through database searching

47 references were found from
manual searchers or publications of
the registered studies

306 references after removing duplicates

306 records screened

123 of records
excluded

183 of full-text articles assessed for
eligibility including 38 guidelines and
expert consensus

33 of full-text
articles

16 publications of systematic
reviews and meta-analyses and 96
publications of RCTs

6 RCTs that directly compared
outcomes between blood pressure
targets

Figure S1 Study flow diagram. Publications of primary RCTs of blood pressure targets (24-29,42-44,104-107); publications of RCTs that
examined efficacy or comparative effectiveness of antihypertensive drugs in 1970–1989 (108-114), 1990–1999 (41,115-135), 2000–2002
(136-152), 2003–2005 (153-174), 2006–2009 (175-190), 2010–2014 (191-207); publications of reviews (3-5,30,31,33-38,40,50,90,93,208,209);
publications of guidelines published in 2010–2014 (59,60,62-66,94,95,97,210-213) and in 2015–2018 (51-56,61,87,96,98,214-217).

Table S1 Relative risk of patient outcomes depending on baseline or attained blood pressure in adults with diabetes, the results from metaanalyses of aggregate data from randomized controlled clinical trials
Outcome

Blood pressure

Relative risk

No. of participants (studies)

Meta-regression of aggregate data by baseline blood pressure
All-cause mortality

10 mmHg lower baseline SBP

1.04 (0.98–1.10)

73,738 (49 RCTs) (31)

All-cause mortality

10 mmHg lower baseline DBP

1.08 (0.99–1.18)

73,738 (49 RCTs) (31)

Cardiovascular mortality

10 mmHg lower baseline SBP

1.15 (1.03–1.29)

73,738 (49 RCTs) (31)

Cardiovascular mortality

10 mmHg lower baseline DBP

1.28 (1.05–1.55)

73,738 (49 RCTs) (31)

End-stage renal disease

10 mmHg lower baseline SBP

1.05 (0.90–1.22)

73,738 (49 RCTs) (31)

End-stage renal disease

10 mmHg lower baseline DBP

1.13 (0.88–1.44)

73,738 (49 RCTs) (31)

Heart failure

10 mmHg lower baseline SBP

1.05 (0.93–1.20)

73,738 (49 RCTs) (31)

Heart failure

10 mmHg lower baseline DBP

1.11 (0.90–1.36)

73,738 (49 RCTs) (31)

Myocardial infarction

10 mmHg lower baseline SBP

1.12 (1.03–1.22)

73,738 (49 RCTs) (31)

Myocardial infarction

10 mmHg lower baseline DBP

1.11 (0.98–1.26)

73,738 (49 RCTs) (31)

Stroke

10 mmHg lower baseline SBP

1.07 (0.98–1.18)

73,738 (49 RCTs) (31)

Stroke

10 mmHg lower baseline DBP

1.09 (0.93–1.27)

73,738 (49 RCTs) (31)

Subgroup meta-analysis of aggregate data by baseline blood pressure
All-cause mortality

Baseline SBP >150 mmHg

0.89 (0.80–0.99)

12,824 (16 RCTs) (31)

Cardiovascular mortality

Baseline SBP >150 mmHg

0.75 (0.57–0.99)

9,073 (11 RCTs) (31)

Myocardial infarction

Baseline SBP >150 mmHg

0.74 (0.63–0.87)

9,914 (13 RCTs) (31)

Stroke

Baseline SBP >150 mmHg

0.77 (0.65–0.91)

11,444 (15 RCTs) (31)

Heart failure

Baseline SBP >150 mmHg

0.73 (0.53–1.01)

6,510 (7 RCTs) (31)

End-stage renal disease

Baseline SBP >150 mmHg

0.82 (0.71–0.94)

4,814 (5 RCTs) (31)

All-cause mortality

Baseline SBP 140–150 mmHg

0.87 (0.78–0.98)

24,652 (10 RCTs) (31)

All-cause mortality

Baseline SBP >140mmHg

0.73 (0.64–0.84)

30,998 (13 RCT) (93)

Cardiovascular mortality

Baseline SBP 140–150 mmHg

0.87 (0.71–1.05)

24,243 (9 RCTs) (31)

Cardiovascular disease

Baseline SBP >140mmHg

0.74 (0.65–0.85)

29,044 (11RCT) (93)

Myocardial infarction

Baseline SBP 140–150 mmHg

0.84 (0.76–0.93)

23,286 (7 RCTs) (31)

Stroke

Baseline SBP 140–150 mmHg

0.92 (0.83–1.01)

30,135 (9 RCTs) (31)

Stroke

Baseline SBP >140mmHg

0.74 (0.74–0.86)

36,934 (14 RCT) (93)

Heart failure

Baseline SBP 140–150 mmHg

0.80 (0.66–0.97)

12,723 (7 RCTs) (31)

End-stage renal disease

Baseline SBP 140–150 mmHg

0.91 (0.74–1.12)

21,376 (6 RCTs) (31)

All-cause mortality

Baseline SBP <140 mmHg

1.05 (0.95–1.16)

24,350 (14 RCTs) (31)

All-cause mortality

Baseline SBP <140 mmHg

1.07 (0.92–1.26)

12,559 (7 RCTs) (93)

Cardiovascular mortality

Baseline SBP <140 mmHg

1.15 (1.00–1.32)

22,439 (10 RCTs) (31)

Cardiovascular disease

Baseline SBP <140 mmHg

0.96 (0.88–1.05)

21,574 (6 RCTs) (93)

Myocardial infarction

Baseline SBP <140 mmHg

1.00 (0.87–1.15)

18,051 (9 RCTs) (31)

Stroke

Baseline SBP <140 mmHg

0.81 (0.53–1.22)

17,911 (8 RCTs) (31)

Stroke

Baseline SBP <140 mmHg

0.69 (0.69–0.92)

17,127 (5 RCT) (93)

Heart failure

Baseline SBP <140 mmHg

0.90 (0.79–1.02)

17,392 (8 RCTs) (31)

End-stage renal disease

Baseline SBP <140 mmHg

0.97 (0.80–1.17)

19,973 (7 RCTs) (31)

Cardiovascular mortality

Baseline SBP <130 mmHg

2.95 (0.43–20.20)

4,946 (2 RCTs) (37)

All-cause mortality

Baseline DBP >90 mmHg

0.85 (0.73–1.00)

6,591 (9 RCTs) (31)

Cardiovascular mortality

Baseline DBP >90 mmHg

0.70 (0.55–0.89)

4,452 (6 RCTs) (31)

Myocardial infarction

Baseline DBP >90 mmHg

0.79 (0.62–1.00)

3,681 (6 RCTs) (31)

Stroke

Baseline DBP >90 mmHg

0.74 (0.58–0.94)

5,211 (8 RCTs) (31)

Heart failure

Baseline DBP >90 mmHg

0.50 (0.29–0.85)

1,259 (2 RCTs) (31)

End-stage renal disease

Baseline DBP >90 mmHg

0.96 (0.14–6.76)

1,259 (2 RCTs) (31)

All-cause mortality

Baseline DBP 80–90 mmHg

0.90 (0.82–0.99)

25,779 (16 RCTs) (31)

Cardiovascular mortality

Baseline DBP 80–90 mmHg

0.91 (0.78–1.07)

24,842 (13 RCTs) (31)

Myocardial infarction

Baseline DBP 80–90 mmHg

0.85 (0.76–0.95)

24,861 (13 RCTs) (31)

Stroke

Baseline DBP 80–90 mmHg

0.92 (0.83–1.03)

30,604 (14 RCTs) (31)

Heart failure

Baseline DBP 80–90 mmHg

0.81 (0.67–0.97)

13,322 (11 RCTs) (31)

End-stage renal disease

Baseline DBP 80–90 mmHg

0.83 (0.72–0.94)

20,912 (8 RCTs) (31)

All-cause mortality

Baseline DBP <80 mmHg

0.97 (0.89–1.06)

29,456 (15 RCTs) (31)

Cardiovascular mortality

Baseline DBP <80 mmHg

1.08 (0.82–1.41)

27,091 (11 RCTs) (31)

Myocardial infarction

Baseline DBP <80 mmHg

0.90 (0.79–1.02)

22,709 (10 RCTs) (31)

Stroke

Baseline DBP <80 mmHg

0.86 (0.70–1.05)

23,675 (10 RCTs) (31)

Heart failure

Baseline DBP <80 mmHg

0.89 (0.80–1.00)

22,044 (9 RCTs) (31)

End-stage renal disease

Baseline DBP <80 mmHg

0.97 (0.83–1.13)

23,992 (8 RCTs) (31)

Meta-regression of aggregate data by attained blood pressure
All-cause mortality

Each 10 mmHg lower attained SBP

0.94 (0.89–0.99)

53,344 (20 RCTs) (33)

All-cause mortality

Each 10 mmHg lower attained SBP

1.02 (0.93–1.12)

73,738 (49 RCTs) (31)

All-cause mortality

Each 10 mmHg lower attained DBP

1.07 (0.93–1.23)

73,738 (49 RCTs) (31)

Cardiovascular mortality

Each 10 mmHg lower attained SBP

1.20 (0.99–1.44)

73,738 (49 RCTs) (31)

Cardiovascular mortality

Each 10 mmHg lower attained DBP

1.35 (0.98–1.86)

73,738 (49 RCTs) (31)

Coronary heart disease

Each 10 mmHg lower attained SBP

0.88 (0.80–0.97)

52,129 (19 RCTs) (33)

Major cardiovascular events

Each 10 mmHg lower attained SBP

0.88 (0.82–0.94)

59,773 (23 RCTs) (33)

Myocardial infarction

Each 10 mmHg lower attained SBP

1.09 (0.98–1.21)

73,738 (49 RCTs) (31)

Myocardial infarction

Each 10 mmHg lower attained DBP

1.13 (0.96–1.33)

73,738 (49 RCTs) (31)

Heart failure

Each 10 mmHg lower attained SBP

0.90 (0.83–0.98)

41,960 (13 RCTs) (33)

Heart failure

Each 10 mmHg lower attained SBP

1.05 (0.90–1.22)

73,738 (49 RCTs) (31)

Heart failure

Each 10 mmHg lower attained DBP

1.11 (0.90–1.36)

73,738 (49 RCTs) (31)

End-stage renal disease

Each 10 mmHg lower attained SBP

1.02 (0.85–1.24)

73,738 (49 RCTs) (31)

End-stage renal disease

Each 10 mmHg lower attained DBP

1.11 (0.88–1.41)

73,738 (49 RCTs) (31)

Renal failure

Each 10 mmHg lower attained SBP

0.92 (0.84–1.01)

28,190 (9 RCTs) (33)

Stroke

Each 10 mmHg lower attained SBP

0.74 (0.65–0.84)

58,064 (21 RCTs) (33)

Stroke

Each 10 mmHg lower attained SBP

0.97 (0.82–1.13)

73,738 (49 RCTs) (31)

Stroke

Each 10 mmHg lower attained DBP

0.95 (0.75–1.21)

73,738 (49 RCTs) (31)

Subgroup meta-analysis of aggregate data by attained blood pressure
All-cause mortality

–

0.92 (0.87–0.96)

66,130 (45 RCTs) (31)

All-cause mortality

Attained SBP >140

0.96 (0.86–1.06)

21,876 (13 RCTs) (31)

All-cause mortality**

Attained SBP ≥140

0.98 (0.89–1.07)

11,559 (9 RCTs) (37)

All-cause mortality**

Attained SBP 130–139

0.85 (0.78–0.92)

23,714 (11 RCTs) (37)

All-cause mortality*

Attained SBP 130–139

0.81 (0.49–1.35)

1,654 (4 RCTs) (37)

All-cause mortality

Attained SBP 130–140

0.86 (0.79–0.93)

28,900 (18 RCTs) (31)

All-cause mortality**

Attained SBP <130

1.00 (0.82–1.21)

6,117 (2 RCTs) (37)

All-cause mortality*

Attained SBP <130

1.44 (0.81–2.57)

4,946 (2 RCTs) (37)

All-cause mortality

Attained SBP <130

1.10 (0.91–1.33)

11,050 (9 RCTs) (31)

All-cause mortality

Attained DBP >80 mmHg

0.95 (0.86–1.06)

13,092 (13 RCTs) (31)

All-cause mortality

Attained DBP 75–80 mmHg

0.86 (0.75–0.98)

14,059 (13 RCTs) (31)

All-cause mortality

Attained DBP <75

0.97 (0.89–1.04)

34,675 (14 RCTs) (31)

Cardiovascular mortality

–

0.92 (0.82–1.03)

59,956 (33 RCTs) (31)

Cardiovascular mortality

Attained SBP >140

0.87 (0.71–1.07)

20,703 (11 RCTs) (31)

Cardiovascular mortality**

Attained SBP ≥140

0.92 (0.75–1.13)

10,386 (10 RCTs) (37)

Cardiovascular mortality**

Attained SBP 130–139

0.79 (0.67–0.93)

22,942 (7 RCTs) (37)

Cardiovascular mortality*

Attained SBP 130–139

0.61 (0.15–2.47)

2459 (4 RCTs) (37)

Cardiovascular mortality

Attained SBP 130–140

0.86 (0.72–1.04)

25,095 (12 RCTs) (31)

Cardiovascular mortality**

Attained SBP <130

1.12 (0.77–1.63)

6,117 (2 RCTs) (37)

Cardiovascular mortality

Attained SBP <130 mmHg

1.26 (0.89–1.77)

10,587 (7 RCTs) (31)

Cardiovascular mortality

Attained DBP >80 mmHg

0.71 (0.53–0.97)

11,229 (10 RCTs) (31)

Cardiovascular mortality

Attained DBP 75–80 mmHg

0.85 (0.69–1.05)

13,040 (10 RCTs) (31)

Cardiovascular mortality

Attained DBP <75 mmHg

1.16 (0.92–1.47)

32,116 (10 RCTs) (31)

Coronary heart disease**

Attained SBP ≥140

0.72 (0.60–0.85)

11,559 (9 RCTs) (37)

Coronary heart disease**

Attained SBP 130–139

0.86 (0.78–0.94)

22,942 (10 RCTs) (37)

Coronary heart disease*

Attained SBP 130–139

0.67 (0.29–1.55)

1,274 (3 RCTs) (37)

Coronary heart disease*

Attained SBP <130

0.67 (0.40–1.14)

4,946 (2 RCTs) (37)

Myocardial infarction

–

0.87 (0.81–0.94)

53,512 (31 RCTs) (31)

Myocardial infarction

Attained SBP >140 mmHg

0.82 (0.72–0.92)

21,286 (12 RCTs) (31)

Myocardial infarction

Attained SBP 130–140 mmHg

0.88 (0.79–0.97)

23,828 (11 RCTs) (31)

Myocardial infarction

Attained SBP <130 mmHg

0.94 (0.76–1.15)

6,137 (6 RCTs) (31)

Myocardial infarction

Attained DBP >80 mmHg

0.76 (0.63–0.93)

9,608 (8 RCTs) (31)

Myocardial infarction

Attained DBP 75–80 mmHg

0.81 (0.72–0.91)

13,650 (12 RCTs) (31)

Myocardial infarction

Attained DBP <75 mmHg

0.95 (0.84–1.07)

27,993 (9 RCTs) (31)

Heart failure

–

0.82 (0.75–0.89)

40,196 (25 RCTs) (31)

Heart failure

Attained SBP >140 mmHg

0.83 (0.68–1.00)

19,060 (9 RCTs) (31)

Heart failure**

Attained SBP ≥140

0.86 (0.70–1.05)

8,743 (5 RCTs) (37)

Heart failure

Attained SBP 130–140 mmHg

0.81 (0.70–0.94)

11,568 (8 RCTs) (31)

Heart failure**

Attained SBP 130–139

0.82 (0.69–0.97)

20,952 (8 RCTs) (37)

Heart failure

Attained SBP <130 mmHg

0.93 (0.71–1.21)

5,997 (5 RCTs) (31)

Heart failure**

Attained SBP <130

0.89 (0.65–1.23)

6,117 (2 RCTs) (37)

Heart failure

Attained DBP >80 mmHg

0.72 (0.45–1.15)

7,656 (5 RCTs) (31)

Heart failure

Attained DBP 75–80 mmHg

0.79 (0.65–0.96)

11,135 (9 RCTs) (31)

Heart failure

Attained DBP <75 mmHg

0.90 (0.79–1.01)

17,834 (8 RCTs) (31)

Stroke

–

0.87 (0.79–0.96)

59,490 (32 RCTs) (31)

Stroke**

Attained SBP ≥140 mmHg

0.89 (0.74–1.07)

11,730 (10 RCTs) (37)

Stroke

Attained SBP >140 mmHg

0.90 (0.76–1.06)

22,045 (14 RCTs) (31)

Stroke

Attained SBP 130–140 mmHg

0.91 (0.83–1.00)

30,342 (12 RCTs) (31)

Stroke**

Attained SBP 130–139

0.85 (0.75–0.96)

28,685 (11 RCTs) (37)

Stroke*

Attained SBP 130–139

0.89 (0.45–1.78)

1,274 (3 RCTs) (37)

Stroke**

Attained SBP <130

0.66 (0.49–0.88)

5,839 (3 RCTs) (37)

Stroke*

Attained SBP <130

1.36 (0.55–3.39)

4,946 (2 RCTs) (37)

Stroke

Attained SBP <130 mmHg

0.65 (0.42–0.99)

7,103 (6 RCTs) (31)

Stroke

Attained DBP >80 mmHg

0.87 (0.73–1.04)

11,011 (10 RCTs) (31)

Stroke

Attained DBP 75–80 mmHg

0.86 (0.75–0.97)

19,380 (12 RCTs) (31)

Stroke

Attained DBP <75 mmHg

0.87 (0.70–1.08)

29,099 (10 RCTs) (31)

Stroke + CHD**

Attained SBP ≥140

0.80 (0.71–0.90)

11,568 (9 RCTs) (37)

Stroke + CHD**

Attained SBP 130–139

0.85 (0.78–0.91)

25,060 (11 RCTs) (37)

Stroke + CHD*

Attained SBP 130–139

0.73 (0.51–1.04)

2,858 (5 RCTs) (37)

Stroke + CHD*

Attained SBP <130

0.80 (0.51–1.26)

4,946 (2 RCTs) (37)

Stroke + CHD + HF**

Attained SBP ≥140

0.85 (0.74–0.97)

9,003 (7 RCTs) (37)

Stroke + CHD + HF**

Attained SBP 130–139

0.87 (0.80–0.94)

30,032 (12 RCTs) (37)

Stroke + CHD + HF*

Attained SBP <130

0.84 (0.60–1.19)

862 (2 RCTs) (37)

End-stage renal disease

–

0.88 (0.80–0.97)

47,439 (18 RCTs) (31)

End-stage renal disease

Attained SBP >140 mmHg

0.88 (0.76–1.03)

18,287 (7 RCTs) (31)

End-stage renal disease

Attained SBP 130–140 mmHg

0.84 (0.66–1.07)

17,912 (6 RCTs) (31)

End-stage renal disease

Attained SBP <130 mmHg

1.01 (0.71–1.43)

9,964 (5 RCTs) (31)

End-stage renal disease

Attained DBP >80 mmHg

0.77 (0.39–1.52)

6,171 (3 RCTs) (31)

End-stage renal disease

Attained DBP 75–80 mmHg

0.81 (0.71–0.93)

8,437 (7 RCTs) (31)

End-stage renal disease

Attained DBP <75 mmHg

0.98 (0.84–1.14)

31,555 (8 RCTs) (31)

*, low/moderate cardiovascular risk; **,high/very high cardiovascular risk. CHD, coronary heart disease; DBP, diastolic blood pressure; HF,
heart failure; RCT, randomized controlled trial; RR, relative risk; SBP, systolic blood pressure.

Table S2 GRADE summary of findings. Harms of blood pressure control in adults with diabetes mellitus (low-quality evidence from published
aggregate data meta-analyses of any antihypertensive treatments)
Risk with intervention
per 1,000 (95% CI)

Risk with comparator
per 1,000

Relative measure of
association

No. of participants
(studies)

Cardiovascular mortality; baseline
SBP <130 mmHg

6

2

RR: 3.96 (1.33–11.84);
2.95 (0.43–20.20)

4,946 (2 RCTs) (37)

Cardiovascular mortality; baseline
SBP <140 mmHg

NR

NR

RR: 1.15 (1.00–1.32)

22,439 (10 RCTs) (31)

Cardiovascular mortality; each 10
mmHg lower baseline SBP

NR

NR

RR: 1.15 (1.03–1.29)

73,738 (49 RCTs) (31)

Cardiovascular mortality; each 10
mmHg lower baseline DBP

NR

NR

RR: 1.28 (1.05–1.55)

73,738 (49 RCTs) (31)

Myocardial infarction; each 10
mmHg lower baseline SBP

NR

NR

RR: 1.12 (1.03–1.22)

73,738 (49 RCTs) (31)

Outcome

Population: adults with diabetes; Settings: outpatient; Intervention: antihypertensive treatment; Comparator: control as no active
antihypertensive treatment; CI, confidence interval; DBP, diastolic blood pressure; GRADE, Grading of Recommendations Assessment,
Development and Evaluation; NR, not reported; RCT, randomized controlled trial; RR, relative risk; SBP, systolic blood pressure.

Table S3 Guideline recommendations regarding blood pressure targets in adults with diabetes
Organization

Recommendations

World Health Organization (WHO); A Global Brief on
Hypertension, 2013 (4,94)

This guideline recommends that target blood pressure in patients with
diabetes should be <130/80 mmHg

Eighth Joint National Committee (JNC 8). Evidence-based
Guideline for the Management of High Blood Pressure in
Adults: Report from the Panel Members Appointed
to the JNC 8, 2014 (53,95) (AGREE II score: 78%)

This guideline recommends initiating pharmacologic treatment to lower
blood pressure at SBP 140 mmHg or DBP 90 mmHg and treat to a goal
of SBP <140/90 mmHg in all adults with diabetes

AHA/ASA Guidelines for the Prevention of Stroke in Patients
With Stroke or Transient Ischemic Attack: A Guideline
for Healthcare Professionals from the American Heart
Association/American Stroke Association, 2011–2017 (56,59)

This guideline recommends that in adults with diabetes and hypertension,
antihypertensive drug treatment should be initiated at a blood pressure
of 130/80 mmHg or higher with a treatment goal of <130/80 mmHg

American Diabetes Association. Position Statement on the
Standards of Medical Care in Diabetes, 2018 (54,55,60,61)
(AGREE II score not available)

This guideline recommends that most patients with diabetes and
hypertension should be treated to an SBP goal of <140/90 mmHg; lower
SBP and DBP targets, such as 130/80 mmHg, may be appropriate for
individuals at high risk of cardiovascular disease, if they can be achieved
without undue treatment burden

American Association of Clinical Endocrinologists and
American College of Endocrinology. Clinical Practice
Guidelines for Developing a Diabetes Mellitus Comprehensive
Care Plan, 2015 (96) (AGREE II score: 53%)

The blood pressure goal for persons with diabetes mellitus or
prediabetes should be individualized and should generally be about
130/80 mmHg; a more intensive goal (e.g., <120/80 mmHg) should be
considered for some patients, provided this target can be reached safely
without adverse effects from medication; more relaxed goals may be
considered for frail patients with complicated comorbidities or those who
have adverse medication effects

Clinical Practice Guidelines for the Management of
Hypertension in the Community: A Statement by the
American Society of Hypertension and the International
Society of Hypertension Clinical Practice Guidelines for the
Management of Hypertension in the Community: A Statement
by the American Society of Hypertension and the International
Society of Hypertension (97)

This guideline recommends that patients with diabetes should be treated
to <140/90 mmHg; this guideline acknowledges that other guidelines
have recommended diagnostic values of 130/80 mmHg for patients with
diabetes or chronic kidney disease. However, the clinical benefits of
this lower target have not been established; some experts recommend
<130/80 mmHg if albuminuria is present in patients with comorbid
chronic kidney disease

The American Geriatrics Society Guidelines for Improving the
Care of Older Adults With Diabetes Mellitus, 2013 (66)

This guideline states that if an older adult has diabetes and requires
medical therapy for hypertension, then the target blood pressure should
be less than 140/90 mmHg if it is tolerated; there is potential harm in
lowering SBP to less than 120 mmHg in older adults with type 2 diabetes
mellitus (1B)

American Academy of Family Physicians, 2017 (98)

The AAFP continues to endorse the 2014 Evidence-Based Guidelines for
the Management of High Blood Pressure in Adults, developed by panel
members appointed to the Eighth Joint National Committee, with a blood
pressure target of <140/80 mmHg

2013 ESH/ESC Guidelines for the Management of Arterial
Hypertension: The Task Force for the Management of Arterial
Hypertension of the European Society of Hypertension (ESH)
and of the European Society of Cardiology (ESC) (65)

This guideline recommends an SBP goal of <140/90 mmHg in patients
with diabetes

The National Institute for Health and Care Excellence,
2011 (63); Type 2 Diabetes in Adults: Management, 2015 (51)

This guideline recommends treating adults with type 2 diabetes and
arterial hypertension to achieve blood pressure <140/80 mmHg
(<130/80 mmHg if there is kidney, eye, or cerebrovascular damage)

Scottish Intercollegiate Guidelines Network. Management of
Diabetes: A National Clinical Guideline (62)
(AGREE II score: 88%)

This guideline recommends target blood pressure <130/80 mmHg in
patients with diabetes; in patients with diabetes and kidney disease,
blood pressure should be reduced to the lowest achievable level to slow
the rate of decline of glomerular filtration rate and reduce proteinuria

Canadian Hypertension Education Program (CHEP) Guidelines
for Pharmacists, 2013 (64)

This guideline recommends that patients with kidney disease and
concomitant diabetes should be treated to a target of <130/80 mmHg
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